New


Help your patients save up to $360 on their LIDODERM prescriptions
by printing an instant savings card now
Learn More

For formulary information, call our hotline at 1-888-LIDOHCP or visit EndoFormularyLink.com
Learn More

Register to request samples, see a sales representative, or receive additional information on LIDODERM.
Learn More

The LIDODERM patch is composed of an adhesive material, containing 5% lidocaine (700mg) in an aqueous base.3 LIDODERM is thought to work by penetrating the skin and binding to receptors within the dermis.4 It is suggested that lidocaine binds to the receptors within the sodium channel, blocking the influx of sodium ions.4 It is believed that this stabilizes the neuronal activity by interrupting the pain signal and reducing the potential for central sensitization.3,4,5 The exact mechanism of action of LIDODERM is not known. The LIDODERM patch can also provide a mechanical barrier against clothing and breezes.4

Important Safety Information

LIDODERM® (lidocaine patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.

LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.

Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.

Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.

Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.

Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.

Allergic reactions, although rare, can occur.

During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.

When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.

Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

Before prescribing LIDODERM, please refer to the full Prescribing Information.

References

  1. Cluff RS, Rowbotham MC. Pain caused by herpes zoster infection. Neurol Clin. 1998;16(4):813-832.
  2. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc. 2007;107(suppl 1):S2-S7.
  3. LIDODERM® Complete Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals; 2010.
  4. Galer BS. Today's Therapeutic Trends. 2000;18:1-20.
  5. Argoff CE. Curr Pain Headache Rep. 2003;7(1):34-38.